Celltheon

ABOUT CELLTHEON

Located in the San Francisco Bay Area – a center of excellence in Biotechnology, Celltheon is a leader in mammalian expression technologies. Founded in 2012, the company's vision was to develop a mammalian expression platform that addressed the industry's key pain points:

Low Expression
Sub-optimal Product Quality
Cell Line Instability
Difficulty with process transferability & scalability

As such, the Celltheon SMART™ Technology Platform was developed to address each of these key challenges. Celltheon leverages its platform technology to provide custom cell line and process development services for the biotech/ pharmaceutical industry. Several novel and biosimilar molecules have been developed using the platform such as monoclonal antibodies, Fabs, antibody fragments, difficult to express proteins, etc. In addition, Celltheon has experience with several disease indications such as oncology, inflammation, neurodegeneration, obesity, and various lysosomal storage disorders.

Since its inception, Celltheon has worked on >60 client projects ranging from pre-clinical to clinical stage therapeutics. In addition, two molecules have advanced to BLA and are awaiting commercial approval. Celltheon has granted 11 commercial licenses to date in addition to several R&D licenses.

The Celltheon SMART™ Technology Platform and services significantly reduce time and costs associated with development of biotherapeutics. As an innovative technology development company, Celltheon continues to develop cutting-edge technologies that improve the manufacturability and efficacy of biologics. Celltheon has filed several patent applications and has received broad, granted patents that encompass many applications of its platform technologies. For more information, please contact us at info@celltheon.com.